The approval is supported by data from the phase 3 LITESPARK-011 trial.
News|Articles|February 23, 2026
Conference Preview: Late-Breaking Abstracts at ASCO GU 2026
Author(s)Hannah Clarke
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
Take a look into the top data set to be presented at this year's ASCO GU Cancers Symposium in San Francisco, California.
Advertisement
Advertisement
The late-breaking abstracts (LBAs) at this year’s American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium offer an early look at data that may meaningfully shift clinical decision-making across urologic oncology. As the treatment landscape continues to evolve, particularly with the expansion of targeted therapies, antibody-drug conjugates, and perioperative immunotherapy strategies, this year’s LBA slate reflects a growing emphasis on biomarker-driven care and treatment intensification across disease states.
Related to this article
Pearls & Perspectives: Expanding Sexual Health Conversations Through Digital Media, With Wendy Brant
Amy Pearlman, MD, and Wendy Brant discuss building a digital audience, navigating sexual health content online, and the role of communication in relationships.
Positive safety and efficacy data from 4 clinical studies supported the CE marking.
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
In a head-to-head RCT, Rezūm produced a 4.6-point greater IPSS improvement than combination pharmacotherapy at 1 year, according to Jean-Nicolas Cornu, MD, PhD, FEBU.
The AACU and the WOCN Society urge CMS to protect access to individualized catheter and ostomy supplies as competitive bidding begins in 2028.
Better detection has changed prostate cancer care. Patients choosing radical treatment still need better protection from the disease returning.
Enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) showed the strongest EFS, OS, and PCR associations among neoadjuvant MIBC strategies in a network meta-analysis, although perioperative design limits attribution.
Advertisement
Advertisement